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Children with bronchiectasis have recurrent acute pulmonary exacerbations and many of these
exacerbations require hospital admissionwhen oral therapies fail. However there is no standard-
ized definition and little published data is available about the features of an exacerbation. Our
aim was to determine the clinical and investigational features of exacerbations in bronchiec-
tasis, the proportion that fail to resolve on oral antibiotics and the factors associated with it.
Methods: A retrospective cohort study of 115 respiratory exacerbations from 30 children with
noncystic fibrosis bronchiectasis diagnosed on HRCT chest. Clinical features, investigations
and treatment related to the exacerbations were extracted and analysed.
Results: Increase in frequency of cough (88%) and a change in its character (67%) were the most
common symptoms associated with an exacerbation. Fever (28%), increase in sputum volume
(42%) and purulence (35%) were also common features. Chest pain, dyspnea, hemoptysis and ta-
chypnea were rare. 56% had a worsening in their chest auscultatory findings during an exacerba-
tion. Spirometry was not significantly different between stable and exacerbation state. 35% of
exacerbations failed to respond to oral antibiotic therapy and required hospital admission.
Prophylactic antibiotic therapy was the only significant predictor of failure of oral therapy with
adjusted odds ratio of 6.77 (95% CI 2.06e19.90; pZ 0.003).
Conclusions: Important clinical features of non-CF exacerbation in bronchiectasis were changes
in cough frequency or character, and worsening chest signs; which resolved on therapies.
However there is a high failure rate of oral antibiotic therapy and use of prophylactic antibiotic
therapy increases this risk.
ª 2009 Elsevier Ltd. All rights reserved.and Children’s Respiratory Centre, Royal Children’s Hospital, Herston, Brisbane, Queensland 4029,
þ61 7 36361958.
iffmail.com (N. Kapur).
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Bronchiectasis unrelated to cystic fibrosis (CF) is an
important cause of respiratory morbidity in developing
countries1 and is increasingly being recognised in indige-
nous people of affluent countries.2,3 Children with bron-
chiectasis have acute exacerbations of respiratory illness
and many require hospital admission when oral therapies
fail but there are no published predictors.4 Recurrent
exacerbations may lead to progressive deterioration of lung
function5 and are one of the strongest predictors of poor
quality of life in bronchiectasis.6
In spite of the wide usage of the term ‘‘exacerbation’’,
there is no standardized definition7 in pediatric or adult
literature and indeed little data on associated clinical
features. To date there are no pediatric studies on the
sputum or plasma biomarker of exacerbation or its severity
in bronchiectasis. In adults studies, serum procalcitonin,8
serum amyloid A9 and sputum IL-610 have been shown to
increase with exacerbation, though none were conclusive in
predicting or defining an exacerbation.
As symptoms of bronchiectasis share features, and often
co-exist, with chronic obstructive pulmonary disease
(COPD),10,11 the definition of exacerbation in COPD in adults
by Anthonisen et al12 has been variably extrapolated to
bronchiectasis studies.13,14 However as this definition
includes sputum volume and purulence, it has limited
applicability in young children who usually do not expecto-
rate.15 Moreover, the differences in the pathogenesis of
these two disorders16,17 make this extrapolation even more
inappropriate for use in children. Due to the absence of
a validated definition, even less is known about the features
associated with treatment success or failure with oral or
intravenous antibiotics, influence of viral respiratory
illnesses, changes in spirometry and sputum microbiology
during an exacerbation. A standardized definition of, and an
understanding of features associated with, exacerbations is
not only important for clinicians, especially non-pulmonol-
ogists who look after children with non-CF bronchiectasis,
but also for research studies. There are currently no pub-
lished studies that have carefully determined the clinical
features associated with respiratory exacerbations of non-
CF bronchiectasis in children.
In this study, we conducted a retrospective review of all
physician-diagnosed exacerbations in a cohort of children
with non-CF bronchiectasis. In these children with a respi-
ratory exacerbation, we aimed to determine: (1) the asso-
ciated clinical and investigational features; (2) the
proportion of exacerbations requiring hospitalisation after
failing to respond to oral antibiotics; and (3) factors pre-
dicting and associated with treatment failure.
Material and methods
The medical records of children with non-CF bronchiectasis
attending our respiratory clinic between 1997 and 2007 were
reviewed. Here forth all references to bronchiectasis refer to
non-CF bronchiectasis. Data was extracted for all the respi-
ratory clinic visits where there was a ‘‘Respiratory physician
diagnosed exacerbation’’. This definition was based on the
Aspen workshop definition18 of COPD exacerbation as ‘‘asustainedworsening of the patient’s condition from the stable
state and beyond normal day to day variations that is acute in
onset and necessitates a change in regular medication.’’ The
onset of bronchiectasis was defined as being from the date of
the first chest HRCT showing bronchiectasis.
Extracted data were clinical, investigation and treat-
ment based. Clinical data included patient details, date of
exacerbation, cough frequency and character, chest pain,
hemoptysis, fever, features of upper respiratory tract
infection (URTI) and chest signs. The definitions used are
detailed in Appendix 1. Data extracted on lethargy, malaise,
decreased oral intake and exercise intolerance was too
limited to be included in final analysis.
Investigational data included sputum culture, nasopha-
ryngeal aspirate (NPA) for viral pathogens [adenovirus,
respiratory syncytial virus, influenza (A and B), parainfluenza
(1, 2, 3) and human metapneumovirus (All using PCR)], lung
function and chest x-ray (CXR). Treatment data included type
and duration of oral/ intravenous (IV) antibiotic therapy and
proportion admitted for IV antibiotic therapy. Endpoints were
clinical wellbeing or cessation of antibiotic therapy. Follow-
up period was calculated from the date of onset of bronchi-
ectasis to the date of the last clinic visit.
The hospital ethics committee approved this retrospec-
tive arm of a broader prospective study on bronchiectasis
defining an exacerbation.
Statistical analysis
Data are presented as mean SEM when normally distrib-
uted and as median  range when non-normally distrib-
uted. Spirometric values between the exacerbation and
stable state were compared by KruskaleWallis test, with
only one reading per child included in the analysis. Odds
ratio (OR) adjusted for age and gender were calculated
using logistic regression for each variable with ‘‘need for IV
antibiotics’’ as the dependent variable. Data on time to
next exacerbation after oral or IV therapy was compared by
chi square test. Data was analysed on SPSS 14.0 statistical
package.
Results
The charts of 30 children (17 M, 13 F, all Caucasians) with
bronchiectasis were reviewed and data was extracted on
a total of 115 exacerbations. The median age at the time of
diagnosis of bronchiectasis was 5.5 years (range 0.8e13)
and the median duration of follow up was 2 years (range
0.5e7). The median age at the time of analysis was 8.5
years (range 3e17). The median number of exacerbations
per child was 2.5 (range 0e15) while the frequency of
exacerbations was 1.6 (range 0e5) exacerbations per child
per year. The frequency of exacerbations peaked in the
winter months of May and June.
Etiology of underlying bronchiectasis
An underlying etiology of bronchiectasis was identified in 20
(67%) patients. Ten (33%) were classified as idiopathic,
seven (23%) as being due to an immunodeficiency disorder
and 5 (16.7%) as a result of a preceding severe pulmonary
Table 1 Underlying aetiology of non-CF bronchiectasis patients expressed as percentage of total group (nZ 30) with
distribution of exacerbation frequency.
Etiology n (%) Number of exacerbations
Immunodeficiency 7 (23%) 29
Common variable immunodeficiency 4 19
X linked agammaglobinemia 1 6
IgA deficiency with Ataxia telengectasia 1 2
Iatrogenic (Recurrent pneumonia on treatment for Wilm’s Tumour) 1 2
Postinfectious (Adenovirus, tuberculosis, post pneumonia) 5 (16.6%) 11
Esophageal atresia-tracheoesophageal fistula 3 (10%) 14
Primary ciliary dyskinesia 1 (3%) 2
Others 4 (13%) 22
CP with recurrent aspiration 1 4
Operated tetrology of Fallot 1 3
Interstitial lung disease (UIP) 1 15
Associated with unilateral lung hypoplasia 1 0
Idiopathic 10 (33%) 37
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ride <35 mmol/L. 21 children had motility and electron
microscopy studies on cilia obtained from nasal mucosal
biopsy to rule out primary ciliary dyskinesia.
Clinical features of exacerbation
Increase in frequency of cough (88%) and a change in its
character (67%) were the most common symptoms associ-
ated with an exacerbation. Fever was present in 32 (28%)
exacerbations, 15 of which had no features an upper
respiratory tract infection (URTI). Chest pain and/or
hemoptysis was present in 4.3% and 2.6% respectively.
Changes in chest auscultatory findings were recorded in 65
(56%) exacerbations. Details of the clinical features are
included in Table 2. There were no defining features of
exacerbations in 6 (5%).Table 2 Clinical features of exacerbation.
Feature n N % %*
Increased cough frequency 94 107 88 82
Change in cough character 73 109 67 63
Increased sputum volume 48 106 45 42
Increased sputum purulence 41 106 38.5 35.5
URTI 39 107 36 34
Fever 32 98 32.5 28
Nocturnal cough 23 74 31 20
Dyspnea 11 86 12.7 9.5
Chest pain 5 37 13.5 4.3
Hemoptysis 3 18 16.66 2.6
Increased crepititions 55 110 50 48
Increased wheeze 37 110 33.5 32
Increased work of
breathing/Tachypnea
10 92 11 8.6
nZ Number of exacerbations with defined feature.
NZ Number of exacerbations in which the information is
available.
%Z Percentage of those with information available.
%*Z Percentage if denominator considered 115 i.e. missing
information meaning feature not present.Investigations
Spirometry data was available from 16 children. The
median FEV1% predicted during exacerbation was 78.5%
(range 36e95.4) compared to the stable state of 82.5%
(range 43.7e103) (pZ 0.36). Similarly, there was no
statistically significant difference in FVC% predicted during
exacerbation (median 81%, range 50.9e102) and stable
state (median 85.5%, range 52.4e114) (pZ 0.34), though
for both results the sample size was small. 6 children had
FEV1/FVC ratio of less than 0.75 in exacerbation state, 4 of
these had similar ratios even in stable state.
Sputum/bronchoalveolar lavage (BAL) culture was
obtained in 58 exacerbations from 18 children with patho-
genic organisms identified in 36 (62%) (Hemophilus influ-
enzae-20, Streptococcus pneumoniae-10, Moraxella
catarrhalis-5, Staphylococcus aureus-2, Pseudomonas aer-
uginosa-4). Sputum/BAL during a non-exacerbation state
was available from 27 children: 14 were sterile on culture
or reported growth of probable contaminants, 7 cultured
H. influenzae, 3 P. aeruginosa, 2 S. aureus, 2 M. catarrhalis
and 3 cultured S. pneumoniae. All sputum samples were
expectorated spontaneously or during physiotherapy but
were not induced. Of the 39 exacerbations that failed to
respond to oral antibiotics, microbiology was available from
21 exacerbations. Of these 12 had no pathological organ-
isms, 6 had H. influenzae, 2 had S. pneumoniae and 1 had P.
aeruginosa. All isolates of Hemophilus, Pneumococcus and
Moraxella were sensitive to either Ampicillin or Amoxy-
cillin/clavulenic acid. Isolates of Staphylococcus were Flu-
cloxacillin sensitive and all Pseudomonas isolates were
sensitive to Ticarcillin and Ceftazidime. Nasopharyngeal
aspirate was positive for viruses detected by PCR in 4 of the
19 (21.1%) samples (influenza A-2, parainfluenza 2-1 and
adenovirus-1). A CXR was performed during 35 exacerba-
tions, 8 had new changes.
Treatment details
Oral antibiotics were started in 110 exacerbations and the
median duration of treatment was 14 days (range 3e56) with
1684 N. Kapur et al.amoxycillin/clavulanic acid being the most common antibi-
otic prescribed (82%), usually given the ‘‘Duo formation’’ at
22.5 mg/kg/dose two times per day. Decision on antibiotic
type was mostly empirical or occasionally based on previous
culture result or clinical response. Median duration of
treatment for exacerbations not requiring further IV therapy
was 14 days (range 7e56). 81 (70%) exacerbations occurred
while the child was already on prophylactic antibiotics.
Roxithromycin (55%) being most common prophylactic anti-
biotic used, followed by Azithromycin (30%), Cotrimaxazole
(10%) and Amoxycillin/clavulanic acid (4%). In all exacerba-
tions, antibiotic different from the usual prophylactic anti-
biotic was used to treat an exacerbation. Prophylactic
antibiotic therapy was associated with significantly higher
risk of failure of oral antibiotic therapy with an adjusted OR
of 6.77 (95% CI 2.06e19.92, pZ 0.003). No other factor
examined (age, gender, URTI, fever, FEV1 % predicted, FVC %
predicted and sputum culture) was found to be statistically
significant in predicting oral therapy failure on univariate
analysis. (p range 0.107e0.901).
Intravenous antibiotics were started in 39 (35%) exac-
erbations within 4 weeks of starting oral therapy (median
21 days, range 3e28) with failure of cough to become dry
(82%), continued production of purulent sputum (43%) and
failure to reduce cough frequency (54%) being cited as the
most common reasons. The median duration of IV antibiotic
therapy was 12 days (range 3e21) and ceftriaxone (100 mg/
kg/day) was the most frequent antibiotic used. None of the
children were on inhaled antibiotics. As inpatients, each
child also underwent chest physiotherapy by a physiother-
apist twice a day. Post discharge, all children were started
on oral antibiotics.
There was no significant difference in the proportion of
children experiencing an exacerbation within the 3 months
of either oral or IV antibiotic therapy (34.7% vs. 35%
respectively). Similar results were found at 6 months as
well (58% for oral vs. 67% in IV, pZ 0.275). Factors or
combinations of factors used by the physicians to judge the
end of an exacerbation and termination of antibiotic
therapy included a reduced cough frequency (75%), dry
cough (54%), reduced sputum volume (12%), improvement
in lung function (26%) and sputum clearing on culture (12%).Discussion
We retrospectively examined 115 respiratory exacerbations
in 30 children with non-CF bronchiectasis. We found that an
increase in frequency of cough and change in its character,
an increase in sputum volume and purulence and an
increase in crepititions and wheeze were all important
clinical features of an exacerbation. Symptoms of chest
pain, hemoptysis, dyspnea, exercise intolerance, tachyp-
nea and increased work of breathing were uncommon.
Spirometry was generally unhelpful in defining an exacer-
bation. A significant number of exacerbations (35%)
required hospitalised treatment (IV antibiotics and chest
physiotherapy) to resolve exacerbations. The only predictor
of requirement of hospitalisation was current use of
prophylactic antibiotics at time of exacerbation.
Validated definitions of exacerbations are important for
clinical and research purposes and currently no validatedclinical or investigational definition exists in literature.
Clinical definition of exacerbation in COPD,12 which
includes increased dyspnea, sputum volume and purulence,
are being used to define bronchiectasis exacerba-
tions.13,14,19 Clinically, presence of increasing cough,
increasing sputum volume and worsening sputum purulence
has been used to define an exacerbation in adults with
bronchiectasis by Murray et al.20 In the absence of vali-
dated data and our experience that non-respiratory physi-
cians tend to use symptoms of pneumonia (i.e. increase in
respiratory rate and dyspnea) as an indication to increase
standard therapies for treating bronchiectasis, we
reviewed relevant exacerbation data in our cohort of chil-
dren. We found some similarities described in adult studies
but importantly some differences as well. A change in the
character of cough, specifically, a dry cough becoming wet,
has not been reported previously as a significant outcome
variable in adult studies. This is an important finding for the
non-expectorating pediatric groups as cough quality (wet/
dry) reported by parents correlates well with clinician’s
assessment,21 indicating it should be a reliable clinical
feature along with, fever and increased crepitations. These
latter signs have not been reported in adult populations
either.8,22 These findings are in contrast to the poor validity
of wheeze and other respiratory sounds reported by
parents23e25 and dyspnea which constitutes a major feature
of exacerbation in adults with bronchiectasis/COPD13,14,19
but was of limited value in our study. Anecdotally while this
is often obvious to respiratory physicians, non-respiratory
physicians often rely on presence of fever to start antibiotic
therapy for an exacerbation. We found that fever was
absent in 2/3rd of exacerbations. Other parameters to
define an exacerbation and response to treatment reported
in adult studies have been changes in inflammatory
markers, spirometry and quality of life scores19,20 though
these studies were addressed at defining a response to
treatment than defining an exacerbation.
Investigations defining exacerbations have not been
examined in children with non-CF bronchiectasis. As our
study was retrospective, such data were unavailable. In an
adult study,8 serum procalcitonin levels correlated with
symptom score and need for antibiotics. Serum C-reactive
protein, white cell count, sputum cell count and inflam-
matory markers (TNF alpha, IL8 and neutrophil esterase)
have been shown to differ significantly in the exacerbation
state compared to 4 weeks post treatment in adult
studies.19
Using lung function to define an exacerbation is limited
by the inability to perform this in very young or uncooper-
ative children and any age group when unwell. Spirometry
is classically described as being ‘‘obstructive’’ in bronchi-
ectasis1,7,26 though there is no data on how it changes with
exacerbations in children. Since ‘‘asthma like’’ disease is
fairly common in bronchiectasis cohorts,27,28 it would be
reasonable to expect the spirometric parameters to show
a worsened obstructive pattern during an exacerbation.
However, data in adults has shown that the changes in
spirometric parameters observed during an exacerbation
are variable and do not even correlate with symptoms.19,29
There was no significant difference in any of the lung
function parameters during exacerbation and 2 and 4 weeks
after it in adults with bronchiectasis.19 As COPD and CF is
Co
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which tends to be more localised, it is biologically plausible
then FEV1 is a poor marker of exacerbations. Our study did
show a non-significant fall in both the FEV1 but our small
sample size is a limitation here.
In pediatric bronchiectasis, the pathogen isolation rate
from sputum or BAL is between 53% and 67%.1,30e32 Similar
isolation rates (62% during exacerbation and 48% during stable
state) were reported in our study as well. However, when the
bacterial organisms are unchanged, molecular studies to
differentiate between the different strains would be neces-
sary.33 Sputum analysis is further complicated in younger
patients by possible contamination from upper respiratory
tract colonization. Chest radiograph as a modality to monitor
bronchiectasis has been shown to have poor sensitivity.34 We
have too little data (only 30% of exacerbations had a CXR
taken) to draw any conclusions from CXR but our findings
suggest that CXR changes are less important to clinical
symptoms in defining a respiratory exacerbation.
Data from adults with CF suggests that approximately 50%
exacerbations are associated with an upper respiratory viral
infection.35 Similar figures are reported in COPD as well,36
but there is no data available for bronchiectasis or seasonal
variations in illness.7 This data on bronchiectasis is therefore
new and indicates that URTI is common and is likely to occur
during the winter months. A hospital-based study in pedi-
atric bronchiectasis1 has reported exacerbation frequency
of 3 per year on intense medical therapy though higher rates
have been reported in a recent adult study.20 Population
based studies onCOPDhave reported an exacerbation rate of
2.5e3 per year per person.37 Even though our study reports
a lower rate, exacerbations treated in the community by the
general practitioners and paediatricians were not included,
and hence not comparable.
The indications for intravenous therapy are not known or
well defined. In a study on adults with bronchiectasis,8 this
was based on failure of oral antibiotics, culture of patho-
genic organisms sensitive only to IV agents or severity of
exacerbation, though it was unclear how failure to therapy
was measured. A high proportion of children (35%) were
admitted for IV antibiotic therapy in our study due to
failure to resolve symptoms on oral medication. This is
comparable to the 34% exacerbations requiring in patient
treatment in adult bronchiectasis though 62.5% exacerba-
tions failed to respond to oral antibiotics and required IV
antibiotics in that study.20 There are no published guide-
lines to assess response to treatment and successful
outcome is usually based on patient’s and/or treating
physician’s subjective assessment of symptom resolution.
Murray et al20 in a prospective cohort study on adults with
bronchiectasis have shown that reduction in 24-hour
sputum volume, fall in C-reactive protein (CRP), sputum
bacterial clearance and improvement in St George’s
Respiratory Questionnaire (SGRQ) were the most useful
parameters in defining response to treatment, with no
significant change in lung functions. Similar results have
been reported by Courtney et al.19
We also found that use of prophylactic oral antibiotics
increased the likelihood of failure of oral antibiotics as an
effective treatment modality. Children who were on
prophylactic antibiotic therapy at the onset of exacerbation
where at a significantly higher risk of requiring IV therapy.The use of prophylactic antibiotics in the reduction of
exacerbations is therefore arguable. However as this was
a hospital based study involving respiratory physicians, these
factors in addition to selection bias of those with more
severe disease (hence placed on prophylactic antibiotics)
may have influenced the high rates of hospitalisation and the
likelihood of successful therapies. The role of prophylactic
antibiotics in causing colonization with resistant bacteria
leading to oral antibiotic failure is debatable.38 A prospec-
tive study with more stringent and pre-defined criteria for
admission is required to resolve this question.
This study had been specifically aimed to obtain infor-
mation on exacerbations in bronchiectasis; the etiological
distribution, though reported, is unlikely to be represen-
tative of all the children with bronchiectasis from the
region. Etiological distribution in this study for immunode-
ficiency and idiopathic bronchiectasis is similar to some of
the larger studies31,39,40 though there are some notable
differences especially in the relative rarity of PCD in our
study. This could be partially explained by the non avail-
ability of nasal ciliary motility and electron microscopy
report in 9 (30%) children. It is possible that few children in
the idiopathic group or under childhood pneumonia group
may actually have PCD.
Our study is highly constrained by the retrospective
nature that limits complete data on the clinical, investi-
gatory and treatment features of all 115 exacerbations.
The small sample size especially in lung function and
sputum parameters further constrains interpretation.
Nevertheless in the absence of any data on exacerbations
of non-CF bronchiectasis in children, we have described
that an increase in the frequency of cough and changes in
its character are the most important clinical features
associated with a physician diagnosed respiratory exacer-
bation. We have also highlighted that a significant number
of exacerbations (35%) require hospitalisation to achieve
clinical endpoints. Furthermore our new findings include
the importance of viral-induced exacerbations and that
use of prophylactic antibiotics increases the risk of
requiring hospitalisation. Prospective studies aimed at
defining and validating an exacerbation are required to
enable a better understanding of the management and
treatment profiles. Our study also highlight the need for
randomised controlled studies, to determine ‘when, what
and how long’ anti-microbials should be used in people
with bronchiectasis, to advance the best practice of this
neglected condition.
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Appendix 1
Definitions used for data extraction.
Variable Definition
Cough frequency Increased/Decreased/Same.
Based on historical evidence.
Cough character Considered wet if described as
‘‘moist’’, ‘‘wet’’, ‘‘chesty’’ or
‘‘rattly’’. Reliability of this has
been previously shown.21
Baseline dry Documented cough free period
or documented dry cough in
any of the visits in the 12
months period around the
exacerbation.
Change in character
of cough
Those with ‘baseline dry’
developing a moist cough or
those who were baseline moist
became more moist/wet
documented by the physician
Upper respiratory
tract infection
Any documentation of
‘‘rhinnorhea’’ or ‘‘sore throat’’
or ‘‘URTI’’ on history or
examination
Fever History of fever in the last 5
days or if temperature of 38
degree C was documented.
Chest pain/Hemoptysis/
Nocturnal cough/Child or
parent perceived dyspnea
Based on historical evidence.
Chest signs of crepitions/
wheeze
Compared with best state in a
12-month period around the
exacerbation.
Failure of oral antibiotics Need of IV antibiotic therapy
within 4 weeks of starting oral
antibiotics for exacerbation.
1686 N. Kapur et al.References
1. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non-
cystic-fibrosis bronchiectasis in children: a persisting problem
in developing countries. Respiration 2005;72(3):233e8.
2. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Working
group on Indigenous Paediatric Respiratory Health. Bronchi-
ectasis in indigenous children in remote Australian communi-
ties. Med J Aust 2002;177(4):200e4.
3. Singleton R, Morris A, Redding G, et al. Bronchiectasis in alaska
native children: causes and clinical courses. Pediatr Pulmonol
2000;29(3):182e7.
4. Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL. The
course of childhood bronchiectasis: a case report and consid-
erations of hospital use. Int J Circumpolar Health 1998;57(4):
276e9.
5. Ellerman A, Bisgaard H. Longitudinal study of lung function in
a cohort of primary ciliary dyskinesia. Eur Respir J 1997;
10(10):2376e9.
6. Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Vali-
dation of the St. george’s respiratory questionnaire in
bronchiectasis. Am J Respir Crit Care Med 1997;156(2 Pt 1):
536e41.
7. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4enon-
cystic fibrosis bronchiectasis. Thorax 2008;63(3):269e76.8. Loebinger MR, Shoemark A, Berry M, Kemp M, Wilson R. Pro-
calcitonin in stable and unstable patients with bronchiectasis.
Chron Respir Dis 2008;5(3):155e60.
9. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid
a is a biomarker of acute exacerbations of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2008;177(3):
269e78.
10. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacer-
bation indices, and inflammation in chronic obstructive pulmo-
nary disease. Am J Respir Crit Care Med 2004;170(4):400e7.
11. O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and
radiological characterisation of patients diagnosed with
chronic obstructive pulmonary disease in primary care. Thorax
2000;55(8):635e42.
12. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES,
Harding GK, Nelson NA. Antibiotic therapy in exacerbations of
chronic obstructive pulmonary disease. Ann Intern Med 1987;
106(2):196e204.
13. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modi-
fying effects of twice-weekly oral azithromycin in patients with
bronchiectasis. Treat Respir Med 2005;4(2):117e22.
14. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bron-
chiectasis: a 12 month study. Thorax 2005;60(3):239e43.
15. Chang AB, Redding GJ, Everard ML. Chronic wet cough: pro-
tracted bronchitis, chronic suppurative lung disease and
bronchiectasis. Pediatr Pulmonol 2008;43(6):519e31.
16. Parameswaran GI, Murphy TF. Infections in chronic lung
diseases. Infect Dis Clin North Am 2007;21(3):673e95. viii.
17. Gray RD, MacGregor G, Noble D, et al. Sputum proteomics in
inflammatory and suppurative respiratory diseases. Am J
Respir Crit Care Med 2008;178(5):444e52.
18. Rodriguez-Raisin R. Toward a consensus definition for COPD
exacerbations. Chest 2000;117:398se401s.
19. Courtney JM, Kelly MG, Watt A, et al. Quality of life and
inflammation in exacerbations of bronchiectasis. Chron Respir
Dis 2008;5(3):161e8.
20. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing
response to treatment of exacerbations of bronchiectasis in
adults. Eur Respir J 2009;33(2):312e8.
21. Chang AB, Gaffney JT, Eastburn MM, Faoagali J, Cox NC,
Masters IB. Cough quality in children: a comparison of
subjective vs. bronchoscopic findings. Respir Res 2005;6:3.
22. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ,
Wedzicha JA. Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2000;161(5):1608e13.
23. Elphick HE, Sherlock P, Foxall G, et al. Survey of respiratory
sounds in infants. Arch Dis Child 2001;84(1):35e9.
24. Cane RS, McKenzie SA. Parents’ interpretations of children’s
respiratory symptoms on video. Arch Dis Child 2001;84(1):31e4.
25. Cane RS, Ranganathan SC, McKenzie SA. What do parents of
wheezy children understand by ‘‘wheeze’’? Arch Dis Child
2000;82(4):327e32.
26. Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic
fibrosis bronchiectasis in childhood: longitudinal growth and
lung function. Thorax 2008;64(3):246e51.
27. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non-CF
bronchiectasis: clinical and HRCT evaluation. Pediatr Pulmonol
2003;35(6):477e83.
28. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary
function of childhood bronchiectasis and comparison with
cystic fibrosis. Thorax 2006;61(5):414e8.
29. O’Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysi-
ology. Thorax 2006;61(4):354e61.
30. Edwards EA, Asher MI, Byrnes CA. Paediatric bronchiectasis in
the twenty-first century: experience of a tertiary children’s
hospital in new zealand. J Paediatr Child Health 2003;39(2):
111e7.
Exacerbations in noncystic fibrosis bronchiectasis 168731. Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does
knowing the aetiology lead to changes in management? Eur
Respir J 2005;26(1):8e14.
32. Santamaria F, Montella S, Camera L, et al. Lung structure
abnormalities, but normal lung function in pediatric bronchi-
ectasis. Chest 2006 Aug;130(2):480e633.
33. Sethi S. New developments in the pathogenesis of acute
exacerbations of chronic obstructive pulmonary disease. Curr
Opin Infect Dis 2004;17(2):113e9.
34. Currie DC, Cooke JC, Morgan AD, et al. Interpretation of
bronchograms and chest radiographs in patients with chronic
sputum production. Thorax 1987;42(4):278e84.
35. Wat D, Gelder C, Hibbitts S, et al. The role of respiratory
viruses in cystic fibrosis. J Cyst Fibros 2008;7(4):320e8.36. Wedzicha JA. Role of viruses in exacerbations of chronic
obstructive pulmonary disease. Proc Am Thorac Soc 2004;1(2):
115e20.
37. Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epide-
miology. Thorax 2006;61(2):164e8.
38. Evans DJ, Bara A, Greenstone M. Prolonged antibiotics for
purulent bronchiectasis in children and adults. Cochrane Data-
base Syst Rev 2007;(Issue 2). doi:10.1002/14651858.CD001392.
Art. No.: CD001392.
39. Nikolaizik WH, Warner JO. Aetiology of chronic suppurative
lung disease. Arch Dis Child 1994 Feb;70(2):141e2.
40. Santamaria F, Montella S, Pifferi M, et al. A descriptive study of
non-cystic fibrosis bronchiectasis in a pediatric population from
central and southern Italy. Respiration 2009;77(2):160e5.
